Johnson & Johnson Acquires New Position in Neumora Therapeutics, Inc. $NMRA

Johnson & Johnson bought a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,849,445 shares of the company’s stock, valued at approximately $3,144,057. Neumora Therapeutics makes up approximately 0.0% of Johnson & Johnson’s holdings, making the stock its 12th largest holding. Johnson & Johnson owned approximately 1.00% of Neumora Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Neumora Therapeutics in the 3rd quarter valued at about $31,000. Fred Alger Management LLC acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $40,000. Canada Pension Plan Investment Board bought a new stake in Neumora Therapeutics in the second quarter valued at $41,000. Finally, Public Employees Retirement System of Ohio bought a new position in Neumora Therapeutics in the 3rd quarter valued at $44,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded down $0.03 during mid-day trading on Friday, reaching $1.45. 336,285 shares of the company’s stock were exchanged, compared to its average volume of 1,690,438. The business’s fifty day simple moving average is $1.61 and its 200 day simple moving average is $2.09. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. Neumora Therapeutics, Inc. has a one year low of $0.83 and a one year high of $3.65. The firm has a market capitalization of $272.45 million, a PE ratio of -1.18 and a beta of 2.75.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, sell-side analysts expect that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Needham & Company LLC cut their price objective on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Royal Bank Of Canada lowered their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.57.

Insider Activity

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00. Following the sale, the insider directly owned 48,750 shares in the company, valued at approximately $73,125. The trade was a 65.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 453,833 shares of company stock valued at $701,219. Corporate insiders own 26.94% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.